TG THERAPEUTICS, INC. Recognition of Deferred Revenue
TG THERAPEUTICS, INC. (TGTX) reported Recognition of Deferred Revenue of $100.80 thousand for the 12-month period ending 2004-12-31, per its 10-Q filed 2011-11-14.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2011-11-14
| Period end | Recognition of Deferred Revenue 12 month |
|---|---|
| 2004-12-31 | $100.80K 10-Q · filed 2011-11-14 |
| 2003-12-31 | $37.87K 10-Q · filed 2011-11-14 |
| 2002-12-31 | $22.72K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |